Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Wichita, Kansas 67214


RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may be an effective treatment for patients with kidney cancer that has spread to the lung. PURPOSE: Phase II trial to study the effectiveness of sargramostim in treating patients who have kidney cancer that has spread to the lung.

Study summary:

OBJECTIVES: - Determine the 4-month progression-free survival rate and overall survival rate in patients with metastatic renal cell carcinoma to the lung treated with aerosolized sargramostim (GM-CSF). - Determine the toxicity of this regimen in these patients. - Determine the immunomodulatory effects of this regimen in terms of natural killer cells cytotoxicity, and T-cell, B-cell, and dendritic cell activation markers. OUTLINE: This is a multicenter study. Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity. Patients are followed for disease progression and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 21-48 patients will be accrued for this study within 7-20 months.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic renal cell carcinoma for which no known standard therapy that is potentially curative or capable of extending life expectancy exists (e.g., surgery) - Measurable metastatic disease in the lung - At least one unidimensionally measurable lesion at least 20 mm by conventional techniques - No CNS metastases that require treatment PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 12 weeks Hematopoietic - Absolute neutrophil count at least 1,000/mm^3 - Platelet count at least 75,000/mm^3 - Hemoglobin greater than 8.0 g/dL Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN) - AST no greater than 3 times ULN Renal - Creatinine no greater than 2.5 times ULN Pulmonary - No hemoptysis of grade 3 or greater - No reactive airway disease on active therapy Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No uncontrolled infection - No other metastatic malignancy within the past 3 years except basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy - More than 2 weeks since prior immunotherapy - More than 2 weeks since other prior biologic therapy Chemotherapy - More than 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) Endocrine therapy - More than 2 weeks since prior corticosteroids - No concurrent systemic glucocorticoids Radiotherapy - More than 2 weeks since prior radiotherapy - No prior radiotherapy to more than 10% of total lung volume in the radiation field Other - At least 4 weeks since prior bronchodialators - No concurrent immunosuppressive agents



Primary Contact:

Study Chair
Svetomir Markovic, MD, PhD
Mayo Clinic

Backup Contact:


Location Contact:

Wichita, Kansas 67214
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.